Manila Times Business
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment Competitive safety profile with no significant off
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Just now
US military bans BYD vehicles from air base in Japan
Just now
India stirs up its gastronomy with French cooking schools
Just now
Turing Award Laureate Joseph Sifakis Visits CaoCao AI Innovation Center, Witnesses Launch of Trustworthy AI Research Project for Robotaxi Curbside Operations
Just now